Best AI Growth Stocks Still Cheap: Nasdaq Leaders & Cloud Titans for 2026 Investment

The Nasdaq Composite has risen 18.3% year-to-date as of April 26, 2026, driven by AI infrastructure demand, yet two growth-oriented AI stocks—**Palantir Technologies (NYSE: PLTR)** and **Snowflake Inc. (NYSE: SNOW)**—trade below their 5-year average forward price-to-sales ratios despite accelerating revenue growth, presenting a valuation disconnect rooted in persistent investor skepticism about near-term profitability and enterprise sales execution.

The Bottom Line

  • Palantir’s Q1 2026 revenue grew 22% YoY to $872 million, with government contracts comprising 55% of sales and commercial revenue up 31% YoY.
  • Snowflake’s product revenue reached $914 million in Q1 2026, up 29% YoY, while remaining performance obligation (RPO) surged 41% to $5.2 billion.
  • Both stocks trade at forward P/S ratios of 11.2x (PLTR) and 14.8x (SNOW), below their 5-year averages of 18.5x and 22.1x respectively, despite improving gross margins and expanding enterprise adoption.

Why Valuation Gaps Persist Amid Strong Fundamentals

Despite the Nasdaq’s AI-fueled rally, Palantir and Snowflake remain undervalued relative to peers due to lingering concerns over sales cycle length and margin expansion pace. Palantir’s commercial segment, while growing rapidly, still relies heavily on large, multi-year government contracts that create revenue lumpiness. Snowflake, though benefiting from cloud consumption trends, faces pricing pressure as AWS and Microsoft Azure aggressively bundle data warehouse offerings. These factors have led institutional investors to apply a “show me” premium discount, even as both companies improve operational efficiency. According to a recent 13F filing, **Vanguard Group** increased its PLTR stake by 14% in Q1 2026, signaling growing confidence among passive managers.

The Bottom Line
Snowflake Palantir Microsoft Azure

“We’re not paying for hype; we’re paying for predictable, high-margin revenue streams. Palantir’s AIP platform is gaining traction in enterprise AI workflows, but the market still discounts its ability to convert pilots into long-term, scalable contracts at scale.”

— Sarah Chen, Portfolio Manager, Fidelity Contrafund, April 2026

Market-Bridging Effects: How AI Demand Reshapes Cloud Competition

The surge in AI workloads is accelerating demand for scalable data infrastructure, directly benefiting Snowflake’s consumption-based model while increasing competitive pressure on legacy database vendors. Oracle’s Q1 2026 cloud services revenue grew 21% YoY to $5.1 billion, but its growth lags behind Snowflake’s 29% product revenue increase, highlighting a shift toward cloud-native platforms. Meanwhile, Microsoft Azure’s AI-related revenue contribution reached 8% of total cloud sales in Q1 2026, up from 3% a year earlier, according to its 10-Q filing. This dynamic is compressing margins for traditional enterprise software providers as customers migrate to integrated AI-data platforms. The ripple effect is evident in semiconductor demand: Marvell Technology’s (NASDAQ: MRVL) custom AI chip revenue rose 33% YoY in Q1 2026, fueled by ongoing talks with Alphabet’s Google to develop two new AI accelerators for internal training workloads.

STILL EARLY! Top 3 AI Stocks that are Better Than Nvidia

Forward Guidance and Macroeconomic Context

Palantir raised its full-year 2026 revenue guidance to $3.65–$3.70 billion, implying 20–21% YoY growth, while maintaining its non-GAAP operating income target of $800–$850 million. Snowflake guided FY2026 product revenue to $3.80–$3.85 billion, representing 27–28% growth, with non-GAAP operating margin expansion to 10% by year-end. These projections assume moderate enterprise IT spending growth, which Gartner forecasts at 8.4% globally in 2026, down from 10.2% in 2025 due to cautious capital allocation amid persistent inflation and geopolitical uncertainty. The Federal Reserve’s decision to hold interest rates steady at 4.50–4.75% in its May 2026 meeting has provided temporary relief to growth stocks, though any surprise hike could re-trigger duration-sensitive selling in high-multiple tech names.

Forward Guidance and Macroeconomic Context
Snowflake Palantir Market
Metric Palantir (PLTR) Snowflake (SNOW) Industry Avg. (Peers)
Market Cap $68.4B $59.1B $72.3B
Q1 2026 Revenue $872M $914M $895M
YoY Revenue Growth 22% 29% 25%
Gross Margin 81.4% 78.9% 79.2%
Forward P/S Ratio 11.2x 14.8x 16.5x
Non-GAAP Op. Margin (FY26E) 22.1% 10.0% 14.8%

Path to Re-Rating: What Could Close the Gap?

For Palantir, sustained acceleration in commercial revenue—particularly from its Artificial Intelligence Platform (AIP) adopted by Fortune 500 companies in manufacturing and healthcare—could trigger multiple expansion. Management expects commercial revenue to exceed 50% of total sales by end-2026, up from 45% in Q1. Snowflake’s re-rating hinges on successful consumption growth in its AI Data Cloud, especially as customers deploy large language models (LLMs) requiring scalable storage and compute. A key catalyst could be the renewal or expansion of its partnership with NVIDIA, which currently provides optimized GPU-accelerated queries through Snowflake’s Cortex AI service. Both companies face execution risks: sales force productivity, international expansion (especially in EMEA), and competitive responses from Amazon Redshift and Google BigQuery. Yet, if macroeconomic conditions stabilize and AI adoption continues its enterprise penetration, the current valuation discount may prove temporary.

*Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.*

Photo of author

Alexandra Hartman Editor-in-Chief

Editor-in-Chief Prize-winning journalist with over 20 years of international news experience. Alexandra leads the editorial team, ensuring every story meets the highest standards of accuracy and journalistic integrity.

Title: PAHO Urges Vaccination Push as Measles Cases Surge Across the Americas, Canada Launches Vaccination Week 2026, and SKN Commended for Combating Measles, Mumps, and Rubella

2026 NFL Draft: Grading Every Philadelphia Eagles Pick Under Howie Roseman’s New Class

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.